肝动脉化疗栓塞术联合阿帕替尼治疗中晚期原发性肝癌疗效评价

发布时间：2018-04-29 06:34

本文选题：原发性肝癌 + 化疗栓塞术　；参考：《中国肿瘤临床》2017年17期

【摘要】：目的:评价肝动脉化疗栓塞术(transarterial chemoembolization,TACE)联合口服阿帕替尼治疗中晚期肝癌的近期疗效。方法:收集2016年6月至2016年10月于首都医科大学附属北京友谊医院接受TACE联合口服阿帕替尼250 mg/d治疗的21例中晚期原发性肝癌(hepatocellular carcinoma,HCC)患者的临床资料;采用影像学中最新修订的实体瘤疗效评价标准(modified response evaluation criteria in solid tumors,m RECIST),回顾性分析联合治疗1个疗程(平均约28 d)后患者的治疗效果,并对不良反应进行分析。结果:21例患者中,完全缓解(complete response,CR)3例(14.3%),部分缓解(patial response,PR)6例(28.6%),疾病稳定(stable disease,SD)5例(23.8%)。疾病控制率(disease control rate,DCR)为61.9%,客观缓解率(objective rate,ORR)为38.1%。疾病进展(progressive disease,PD)2例(9.5%)。21例患者治疗中出现的不良反应:乏力17例(94.4%),胃肠道症状14例(66.7%),手足综合征4例(19.0%),血压升高4例(19.0%),并出现不同程度的声音嘶哑、头痛头晕、蛋白尿等。结论:TACE联合阿帕替尼对中晚期原发性肝癌的临床治疗近期效果满意,治疗过程中不良反应发生率较高,需给予积极处理。
[Abstract]:Objective : To evaluate the clinical data of patients with advanced hepatocellular carcinoma ( HCC ) treated by TACE combined with transarterial chemotherapy ( TACE ) . Results : In 21 patients , complete response ( CR ) , 3 cases ( 14.3 % ) , partial response ( PR ) 6 cases ( 28.6 % ) , stable disease ( SD ) in 5 cases ( 28.6 % ) , disease control rate ( DCR ) in 2 cases ( 9.5 % ) . There were 14 cases of gastrointestinal symptoms ( 66.7 % ) , 4 cases of hand - foot syndrome ( 19 . 0 % ) , 4 cases ( 19 . 0 % ) of blood pressure increase , and appeared different degree of hogging , headache , dizziness , proteinuria , etc . Conclusion : TACE combined with afatinib has a satisfactory effect in recent clinical treatment of primary hepatic carcinoma .

【作者单位】：首都医科大学附属北京友谊医院放射介入科;
【分类号】：R735.7

【相似文献】